title: [Efficiancy Angiotensin -converting enzyme inhibitors for the clinical practice].
abstract: These clinical trials show the efficiency of therapy with angiotensin-converting enzyme (ACE) inhibitors in essential hypertension (EH), chronic heart failure and coronary heart disease (CHD). The SMILE studies have indicated positive results of the early administration (<24 hours) of zofenopril in patients with acute myocardial infarction (AMI). These results have been confirmed in high-risk patients, including those with hypertension and diabetes mellitus, which enables zofenopril to be recommended for clinical use in patients with EH and CHD. Zofenopril has a better safety profile than other agents.
authors.forename: G V
authors.initials: GV
authors.lastname: Abuladze
authors.forename: M I
authors.initials: MI
authors.lastname: Nebieridze
authors.forename: E V
authors.initials: EV
authors.lastname: Narsiia
authors.forename: I G
authors.initials: IG
authors.lastname: Erkomaishvili
authors.forename: N G
authors.initials: NG
authors.lastname: Pipiia
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002216:Captopril / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D058065:Diabetic Cardiomyopathies / Q000150:complications / Q000628:therapy; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000188:drug therapy*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; C044958:zofenopril; D002216:Captopril